Prostate cancer is the most common malignancy in men, yet its etiology remains obscure. A central theme of the carcinogenic process is uncontrolled cell growth, which is a disturbance in the balance between cell proliferation and cell death. Factors that stimulate cell proliferation enhance the opportunity for accumulation of random genetic errors and emergence of a malignant phenotype. Factors that block apoptosis, which would normally remove DNA-damaged cells from the cycle, may promote continued growth of malignant cells. There is compelling evidence that certain medications may act as risk or protective factors for prostate cancer through a common biological pathway involving altered rates of prostatic cell growth or death. To study the relationships between these frequently used medications and prostate cancer, we propose a population-based case-control study of 1000 cases and 1000 controls, aged 40-74 years, that will test the following hypotheses: 1. Use of nonsteroidal anti-inflammatory drugs is associated with a reduced risk of prostate cancer; 2. Use of statins is associated with a reduced risk of prostate cancer; 3. Use of calcium-channel blockers is associated with an increased risk of prostate cancer; and 4. Use of histamine H2-receptor antagonists is associated with an increased risk of prostate cancer. We also will assess genetic polymorphism in the CYP2C9 gene, which is involved in drug metabolism. Logistic regression models will be used to estimate relative risks of prostate cancer associated with use of each type of medication, adjusting for potential confounding factors. Tumor stage and grade will be used to assess whether associations vary by disease aggressiveness. Given the rising frequency of exposure to some of these medications, the information from this study will be timely and is urgently needed. Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA092579-03
Application #
6608900
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Patel, Appasaheb1 R
Project Start
2001-08-21
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$700,737
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Karyadi, Danielle M; Geybels, Milan S; Karlins, Eric et al. (2017) Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes. Oncotarget 8:1495-1507
Geybels, Milan S; McCloskey, Karen D; Mills, Ian G et al. (2017) Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status. Prostate 77:282-290
Jhun, Min A; Geybels, Milan S; Wright, Jonathan L et al. (2017) Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget 8:43035-43047
Rubicz, Rohina; Zhao, Shanshan; Wright, Jonathan L et al. (2017) Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Mol Oncol 11:140-150
Zhao, Shanshan; Geybels, Milan S; Leonardson, Amy et al. (2017) Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clin Cancer Res 23:311-319
Geybels, Milan S; Fang, Min; Wright, Jonathan L et al. (2017) PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget 8:84338-84348
Luedeke, Manuel; Rinckleb, Antje E; FitzGerald, Liesel M et al. (2016) Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet 25:5490-5499
Rizzardi, Anthony E; Zhang, Xiaotun; Vogel, Rachel Isaksson et al. (2016) Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor ?2 immunohistochemistry in prostate cancer. Diagn Pathol 11:63

Showing the most recent 10 out of 81 publications